eli lilly phase 3 trial retatrutide said Thursday its experimental obesity drug delivered up to 28.3 percent body-weight reduction over 80 weeks in the pivotal TRIUMPH-1 trial, a result nearing the weight-loss range Who Makes Retatrutide? Company Behind

It slows stomach emptying and signals the brain that the body is full

Research from obesity pharmacotherapy trials consistently shows that higher protein intake (targeting 0.8-1.0 grams per pound of goal body weight daily) significantly improves lean mass retention during rapid weight loss

That kind of transparency mattered to me

Tesamorelin addresses what many weight loss peptide approaches miss entirely: the deep abdominal fat that drives metabolic syndrome

The future of weight loss therapy is shifting toward more personalized and metabolically targeted care

Avoid hot, greasy, or strongly flavored foods on nausea days